KalVista Pharmaceuticals (KALV) Total Current Liabilities (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Total Current Liabilities of $38.4 million in Q3 2025, down 15.04% quarter-over-quarter from $45.2 million in Q2 2025, and up 71.23% year-over-year from $22.4 million in Q3 2024.
KalVista Pharmaceuticals' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $38.4 million for Q3 2025.
- In Q3 2025, Total Current Liabilities rose 71.23% year-over-year to $38.4 million; the TTM figure through Jul 2025 stood at $38.4 million (up 71.23% YoY), while the FY2025 annual figure was $45.2 million, up 98.04% from the prior year.
- Total Current Liabilities came in at $38.4 million for Q3 2025 at KalVista Pharmaceuticals, down from $45.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $45.2 million in Q2 2025 to a low of $6.5 million in Q1 2021.
- A 5-year average of $17.5 million and a median of $14.1 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities plunged 33.23% in 2021 and surged 98.04% in 2025, its largest moves.
- KalVista Pharmaceuticals' Total Current Liabilities stood at $10.1 million in 2021, then gained by 11.92% to $11.3 million in 2022, then jumped by 56.81% to $17.8 million in 2023, then surged by 47.11% to $26.1 million in 2024, then soared by 46.95% to $38.4 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $38.4 million, $45.2 million, and $26.1 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 38.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 38.38 Mn |
| Apr 30, 2025 | 45.17 Mn |
| Dec 31, 2024 | 26.11 Mn |
| Oct 31, 2024 | 22.16 Mn |
| Jul 31, 2024 | 22.41 Mn |
| Apr 30, 2024 | 22.81 Mn |
| Jan 31, 2024 | 19.13 Mn |
| Oct 31, 2023 | 17.75 Mn |
| Jul 31, 2023 | 14.13 Mn |
| Apr 30, 2023 | 15.03 Mn |
| Jan 31, 2023 | 11.61 Mn |
| Oct 31, 2022 | 11.32 Mn |
| Jul 31, 2022 | 9.73 Mn |
| Apr 30, 2022 | 11.58 Mn |
| Jan 31, 2022 | 9.65 Mn |
| Oct 31, 2021 | 10.11 Mn |
| Jul 31, 2021 | 8.23 Mn |
| Apr 30, 2021 | 9.77 Mn |
| Jan 31, 2021 | 6.52 Mn |
| Oct 31, 2020 | 9.54 Mn |
| Jul 31, 2020 | 8.46 Mn |
| Apr 30, 2020 | 7.72 Mn |
| Jan 31, 2020 | 9.76 Mn |
| Oct 31, 2019 | 10.47 Mn |
| Jul 31, 2019 | 13.97 Mn |
| Apr 30, 2019 | 18.05 Mn |
| Jan 31, 2019 | 18.83 Mn |
| Oct 31, 2018 | 20.94 Mn |
| Jul 31, 2018 | 22.90 Mn |
| Apr 30, 2018 | 23.22 Mn |
| Jan 31, 2018 | 24.08 Mn |
| Oct 31, 2017 | 3.51 Mn |
| Jul 31, 2017 | 3.84 Mn |
| Apr 30, 2017 | 3.02 Mn |
| Jan 31, 2017 | 3.20 Mn |
| Mar 31, 2016 | 3.85 Mn |
| Dec 31, 2015 | 4.27 Mn |
| Sep 30, 2015 | 3.79 Mn |
| Jun 30, 2015 | 4.17 Mn |
| Mar 31, 2015 | 11.01 Mn |
| Dec 31, 2014 | 7.09 Mn |